Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
|Slideshows|December 5, 2016
AES 2016: Young Investigator Award Research
Author(s)Samantha J. Peterson
Award-winning basic, translational, or clinical epilepsy research covered cannabidiol treatment, outcome predictions, imaging studies, and more.
Advertisement
Award-winning research presentations at the American Epilepsy Society Annual Meeting included cannabidiol treatment, MRI differences in temporal lobe epilepsy, methods to predict surgical outcomes, and more.Â
Advertisement
Related to this article
A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.
A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.
Here's some of what is coming soon to NeurologyLive® this week.
An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
3
First-in-Human Trial Begins for an Antisense Oligonucleotide in KCNT1-Related Epilepsy
4
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
5